A retrospective review of 131 patients with very high risk features (at least one of Gleason score 10, Gleason score 8 or 9 with PSA > 20 ng/mL, clinical T3, >50% positive cores, PSA > 40 ng/mL) treated with EBRT, LDR brachytherapy boost, and ADT had 12-year cancer-specific survival of 87%, biochemical progression-free survival of 87%, and overall survival of 61% [20]. Here, KLK3 is linked to cancer.